The Inactive Form of a Yeast Casein Kinase I Suppresses the Secretory Defect of the sec12 Mutant
IMPLICATION OF NEGATIVE REGULATION BY THE Hrr25 KINASE IN THE VESICLE BUDDING FROM THE ENDOPLASMIC RETICULUM*

Akiko MurakamiDagger §, Keitarou Kimura, and Akihiko NakanoDagger parallel

From the Dagger  Molecular Membrane Biology Laboratory, RIKEN, Wako, Saitama 351-0198 and the  Genetic Engineering Laboratory, National Food Research Institute, Tsukuba, Ibaraki 305-8642, Japan

    ABSTRACT
Top
Abstract
Introduction
References

Sec12p is the guanine nucleotide exchange factor of Sar1 GTPase and functions at the very upstream in the vesicle budding reactions from the endoplasmic reticulum (ER). We previously identified three yeast loci, RST1, RST2, and RST3, whose mutations suppressed the temperature-sensitive growth of the sec12-4 mutant (Nakano, A. (1996) J. Biochem. (Tokyo) 120, 642-646). In the present study, we cloned the wild-type RST2 gene by complementation of the cold-sensitive phenotype of the rst2-1 mutant. RST2 turned out to be identical to HRR25, a gene encoding a dual-specificity casein kinase I in yeast. The rst2-1 mutation, which is now renamed hrr25-2, was due to the T176I amino acid replacement in the kinase domain. This mutation remedied not only the temperature-sensitive growth but also the defect of ER-to-Golgi protein transport of sec12. Immunoprecipitation of the hemagglutinin-tagged Hrr25-2 protein and a subsequent protein kinase assay showed that the kinase activity of the mutant protein was markedly reduced. The overproduction of another kinase-minus mutant of Hrr25p (Hrr25p K38A) slightly suppressed the growth defect of sec12-4 as well. These observations suggest that the reduction of the kinase activity in the mutant protein is important for the suppression of sec12. We propose that Hrr25p negatively regulates the vesicle budding from the ER.

    INTRODUCTION
Top
Abstract
Introduction
References

The secretory pathway begins from the ER.1 By genetic approaches with yeast Saccharomyces cerevisiae, many secretory genes have been identified in the whole pathway, and more than 20 genes are now known to function in the transport from the ER to the Golgi apparatus. Among these genes, SEC12 and SAR1 are believed to play pivotal roles in the earliest step, that is the formation of transport vesicles from the ER. SAR1 encodes a 21-kDa GTPase (Sar1p) (1), which functions as a molecular switch to recruit a coat protein complex, COPII, onto the ER membrane (2); SEC12 codes for a 70-kDa integral membrane protein (Sec12p) in the ER and acts as the guanine nucleotide exchange factor (GEF) toward Sar1p, which converts Sar1p from the inactive GDP form to the active GTP form (3). Sar1p-GTP promotes the assembly of COPII (Sar1p, Sec13p/Sec31p, and Sec23p/Sec24p) (2), budding, formation, and release of vesicles (2, 4). Thus, Sec12p is the most upstream player in the vesicle budding from the ER as far as we know. However, little is known as to when and how the GEF activity of Sec12p is triggered in this earliest event of vesicle budding. The regulation of Sec12p function may be a key issue for understanding the mechanisms of cargo and resident selection in the vesicle budding event.

We recently identified three genetic loci, RST1, RST2, and RST3, whose mutations suppressed the temperature-sensitive (ts) growth defect of the sec12-4 mutant (5). These genes were expected to be the candidates of Sec12p regulators. RST1-1 was a dominant mutation and caused elevated expression of Sec12p. rst2 and rst3 were recessive and gave pleiotropic phenotypes including slow growth at low temperature, aggregation of cells, and heterogeneous glycosylation of Sec12p. In this study, we extended characterization of the rst2-1 mutant and cloned the wild-type RST2 gene by complementation.

    EXPERIMENTAL PROCEDURES

Yeast Strains and Culture Conditions-- The yeast strains used in this study were MBY10-7A (sec12-4 ura3-52 leu2-3, 112 trp1-289 his3 his4 suc gal2 MATa) (6), MBY10-7C (sec12-4 ura3-52 leu2-3, 112 trp1-289 his3 his4 suc gal2 MATalpha ) (6), ANY21 (ura3-52 leu2-3, 112 trp1-289 his3 his4 suc gal2 MATa) (6), STR2 (sec12-4 rst2-1 ura3-52 leu2-3, 112 trp1-289 his3 his4 suc gal2 MATa) (5), and AMY7-4B (2µ HRR25 URA3; hrr25::HIS3 ura3-52 lys2-801 ade2-101 trp1-D63 his3-D200 leu2-D1 MATa) (this study). The cells were grown at 37 °C (for STR2), 30 °C or 23 °C (for MBY10-7A and MBY10-7C) in YP medium (2% (w/v) polypeptone (Nihon Pharmaceutical Co. Ltd., Tokyo, Japan), 1% (w/v) yeast extract (Difco Laboratories, Inc., Detroit, MI)) containing 2% (w/v) glucose (YPD) or in MC medium (0.67% (w/v) yeast nitrogen base without amino acids (Difco Laboratories), and 0.5% (w/v) casamino acids (Difco Laboratories)) containing 2% (w/v) glucose (MCD) supplemented appropriately. For derepression of the GAL1 promoter, MC medium was supplemented with 5% galactose and 0.2% sucrose (MCGS).

Plasmids-- A yeast replication plasmid (pJJ215), a single-copy plasmid (pRS314), a multicopy plasmid (pYO324), and an integration plasmid (pRS304) were described previously (7-9). Another multicopy plasmid, pQR324, was provided by H. Qadota of the Nara Institute of Science and Technology.

Cloning of the RST2 Gene-- For the cloning of the RST2 gene, the strain STR2 (rst2-1 sec12-4), which shows a Cs-Ts+ phenotype, was transformed with a genomic library (10) constructed on YEp13, which contains the LEU2 gene as the selectable marker. Electroporation was used to obtain high transformation efficiency (see below). Transformants were plated in 5-6 ml of regeneration top agar containing 1× MVD, 1 M sorbitol, 2.5% agar, and appropriate supplements and incubated at 24 °C. After 5-6 days, large colonies were picked up, streaked, and further incubated at 15 and 37 °C. Among eight candidates we obtained, one clone (named P2-3) reproducibly conferred Cs+Ts- growth to the STR2 cells. This plasmid was recovered from the yeast transformant. After the confirmation of the phenotypes by retransformation, the genomic insert was subcloned and subjected to further complementation tests.

Transformation by Electroporation-- From a saturation culture in 50 ml of YPD, STR2 cells were harvested and washed two times with sterile distilled water. The cells were resuspended in 20 ml of 0.1 M Tris-HCl, pH 9.4, and 100 µl of 1 M DTT. After incubation at 30 °C for 10 min, the cells were centrifuged at 1800 × g for 5 min and resuspended in the spheroplasting buffer (0.67% yeast nitrogen base, 1 M sorbitol, and 0.5% glucose). Zymolyase-100T (Seikagaku Corp.) (5 mg) was added to the cell suspension, and incubation was continued for 10-20 min at 30 °C. The Zymolyase-treated samples were overlaid on 25 ml of 1.4 M sorbitol solution and centrifuged at 1800 × g. Spheroplasted pellets were resuspended in 0.5 ml of 1 M sorbitol and kept on ice until use for electroporation.

For electroporation, 4 µg of DNA (up to 10 µl) was added to a 100-µl aliquot of the spheroplast suspension. The samples were mixed gently and put on ice 5 min prior to electroporation, and then transferred to a cold sterile cuvette (0.4 cm) and subjected to electroporation (Bio-Rad Gene PulserTM; pulse at 1.5 kV, 25 microfarads, 200 watts for 3 s). Immediately after electroporation, 100 µl of 1 M sorbitol solution was added and the samples were spread on MVD plates (with adequate supplements) containing 1 M sorbitol.

Introduction of the Influenza Hemagglutinin (HA) Tag into HRR25-- The AflII-AflII fragment of HRR25 was amplified with an NheI site created near the 5'-terminus of the ORF by PCR (primer sequences: 5'-TCTATGGACTTAAGAGCTAGCGTAGGAAGGAAATTT-3' and 5'-TCTACCGCTTAAGTATCTGTAGACGCG-3'). The resulting NheI site-containing fragment was used to replace the original HRR25 AflII-AflII fragment. The DNA cassette encoding three tandem repeats of the HA epitope was excised from pYT11 by NheI digestion (11), and inserted into the NheI site of the above construction. The resulting plasmid was named pAM5-2 (2µ 3HA-HRR25 TRP1). The expression of 3HA-HRR25 was confirmed by immunoblotting with the monoclonal anti-HA antibody 16B12 (Berkeley Antibody). A plasmid harboring 3HA-rst2-1, pAM6-2 (2µ 3HA-rst2-1 TRP1), was constructed from pAM1-5 (2µ rst2-1 TRP1) by substituting the AflII-AflII fragment of pAM5-2 for that of pAM1-5. pAM1-5 is the plasmid containing the mutant allele rst2-1, which was obtained by the allele recovery method.

The HRR25 expression plasmid, pAM4-1 (2µ GAL1 promoter 3HA-HRR25 URA3), was constructed as follows. A HindIII site was created just before the initiation codon of HRR25 by PCR. The BamHI-HindIII fragment containing 3HA-HRR25 was subcloned into pYES2 (Invitrogen, Leek, The Netherlands), which is a 2µ-based multicopy plasmid carrying the GAL1 promoter and a selectable URA3 marker.

Site-directed Mutagenesis in 3HA-HRR25-- The K38A mutation in 3HA-HRR25 was created by PCR with the following primers: for N-terminal fragment, 5'-GGCTCGAGGAAAGCATTTTGG-3' (hrr25 XHOI) and 5'-CGATTCCAGAGCGATGGCTAC-3' (hrr25 XHOI KA); for C-terminal fragment, 5'-GTAGCCATCGCTCTGGAATCG-3' (hrr25 NCOI KA) and 5'-CTCGGATCCCCATGGCAAAGAACCCTT-3' (hrr25 NCOI). The mutation was introduced by the first PCR with hrr25 XHOI KA/hrr25 XHOI and hrr25 NCOI KA/hrr25 NCOI and the produced fragments were amplified by the second PCR with hrr25 XHOI and hrr25 NCOI. The resulting 0.9-kb XhoI-NcoI fragment was used to replace the corresponding region of 3HA-HRR25 to yield the 3HA-HRR25 K38A mutant allele.

Immunoprecipitation of HA-Hrr25p and Its Kinase Assay-- Immunoprecipitation kinase assays with HA-tagged Hrr25p were performed by the method described (12, 13) with some modifications. The HRR25 deletion strain (AMY7-4B) was transformed with plasmids containing 3HA-HRR25, 3HA-rst2-1, or non-tagged HRR25 (2µ TRP1) and grown in YPD. Cells in a 100-ml culture were harvested at 2 OD600/ml and resuspended in 500 µl of IPK buffer (50 mM Tris-HCl, pH 7.5, 1% Nonidet P-40, 0.05% SDS, 0.05% sodium deoxycholate, 5 mM EDTA, 5 mM DTT, 100 mM NaCl, 5 µg/ml each of leupeptin, antipain, chymostatin, and pepstatin, and phosphatase inhibitor (0.2 mM sodium orthovanadate, 30 mM sodium pyrophosphate, and 50 mM sodium fluoride)). Glass beads (200 mg) were added to the cell suspension in 2-ml screw-capped tubes, and the samples were lysed by vigorous vortexing without heating. The materials were centrifuged and supernatants were transferred to fresh screw-capped tubes containing 300 µl of IPK buffer. After the addition of 2 µl of 1 mg/ml anti-HA monoclonal antibody (12CA5; Boehringer Mannheim) to each 200 µg of total protein, the samples were kept on ice for 2 h and mixed with 10 µl of 50% Protein A-Sepharose CL-4B at 4 °C for 2 h. Immune complexes were collected by centrifugation for 10 s in a microtube, and washed twice with IPK buffer, twice with 1 M NaCl in IPK buffer without inhibitor, and twice with kinase buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl2, and 1 mM DTT). Each sample was resuspended in 15 µl of kinase buffer and split 1:2; one third was transferred to a fresh screw-capped tube for kinase assays, and the remainder was spun down, aspirated dry, boiled briefly in the 1× SDS-PAGE sampling buffer, and subjected to SDS-PAGE and immunoblotting with the anti-HA antibody.

The immunoprecipitates for the kinase assay were washed again with kinase buffer, dried, and resuspended in 15 µl of kinase buffer prior to preincubation at 37 °C for 10 min. The kinase assay was initiated by adding 5 µl of kinase buffer containing 10 mCi of [gamma -32P]ATP (final ATP concentration = 1 mM; 3000 Ci/mmol; NEN Life Science Products). Reactions were terminated after 15 min with 2 µl of 4× SDS-PAGE sampling buffer and heated to 95 °C for 2 min before electrophoresis. The gels were dried and visualized by autoradiography using BAS2500 (Fuji Film).

    RESULTS

rst2 Suppresses the Secretory Defect of the sec12 Mutation-- To examine whether rst2-1 suppresses not only the temperature-sensitive growth defect but also the secretory defect of the sec12-4 mutation, we performed a pulse-chase and immunoprecipitation experiment with the anti-carboxypeptidase Y (CPY) antibody (Fig. 1, upper panel). In the wild-type cells, newly synthesized CPY undergoes stepwise processing from the 67-kDa ER precursor (p1) through the 69-kDa Golgi precursor (p2) to the 61-kDa mature vacuolar form (m). When the sec12 mutant cells were pulse-labeled for 4 min and chased for 2 h at 37 °C, the p1 form accumulated, indicating that the ER-to-Golgi transport was blocked. Such accumulation of the p1 form was not detected when the sec12-4 rst2-1 double mutant cells were incubated at 37 °C. Normal modification and processing from p1 through p2 to m forms was observed, although the rate was a little slower than that of wild-type cells.


View larger version (67K):
[in this window]
[in a new window]
 
Fig. 1.   The rst2-1 mutation restores the secretory defect of sec12 cells. Cells of MBY10-7A (sec12-4 RST2), ANY21 (SEC12 RST2), and STR2 (sec12-4 rst2-1) were starved for sulfate for 30 min at the indicated temperatures. After 4-min (for CPY) or 5-min (for Gas1p) pulse labeling, cells were chased for the indicated times at the same temperatures. Cell lysates were prepared and subjected to immunoprecipitation, SDS-PAGE, and fluorography. Times are shown in minutes, except for the 2-h points. p1, ER form; p2, Golgi form; m, mature form; i, immature form.

We also performed a pulse-chase experiment on a glycosylphosphatidylinositol-anchored plasma-membrane protein, Gas1p (14, 15) (Fig. 1, lower panel). Like the case of CPY, the immature form (i) of Gas1p accumulated in the sec12 mutant cells after 30-min chase at 37 °C. In contrast, Gas1p was processed to the mature form (m) in the sec12-4 rst2-1 double mutant cells at the restrictive temperature for sec12, 37 °C. These data indicate that the rst2 mutation remedies the secretory defect of the sec12 mutation.

Overproduction of the Sec12 ts protein by the introduction of the mutant gene on a multicopy plasmid (2µ) allows growth of the sec12 ts strain at 37 °C (Fig. 2A; see also Ref. 16). Even a slight increase of the gene dosage by the introduction of the single-copy plasmid (CEN) of sec12 could suppress the ts growth to some extent. We performed immunoblotting analysis using the anti-Sec12p antibody to examine whether the level of Sec12-4p increased in the sec12 rst2 cells to the extent that was able to suppress the sec12 mutant phenotype. As shown in Fig. 2B, the amount of Sec12-4p was slightly increased in the sec12-4 rst2-1 cells as compared with that in the sec12-4 RST2 cells (lanes 3 and 4 versus lanes 1 and 2). Careful quantification of the results of three independent experiments with the amount of Pgk1p as an internal standard indicated that the amount of Sec12-4p was 2-3 times larger in sec12-4 rst2-1 than in sec12-4 RST2. The extent of the increase was almost the same as the case where an extra copy of sec12-4 was supplied by the introduction of a single-copy (CEN) plasmid (lanes 5 and 6). The level of Sar1p was not affected either by the rst2-1 mutation or the introduction of sec12-4 plasmids. These results suggested a possibility that the increase of Sec12-4p by the rst2-1 mutation was the cause of the suppression. However, the effects of the rst2-1 mutation and the increase of Sec12-4 were quite different when the intracellular transport of CPY was examined. As shown in the bottom panel of Fig. 2B, the introduction of the rst2-1 mutation in sec12-4 cells completely remedied the accumulation of the ER form (p1). In contrast, in the cells in which the Sec12-4 levels were raised by sec12-4 plasmids (CEN or 2µ), the accumulation of the p1 CPY was not completely cured even though the ts growth was almost completely suppressed by sec12-4. These observations led us to conclude that the effect of rst2-1 in the suppression of sec12-4 was not due to the increase of the Sec12-4 protein by itself.


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 2.   Expression of the sec12-4 allele in the sec12-4 and sec12-4 rst2-1 mutant cells. A, the growth of sec12 ts mutant cells carrying plasmid-borne sec12-4. Cells of wild-type (ANY21), sec12-4/2µ sec12-4 (MBY10-7A/pAM13-3), sec12-4/CEN sec12-4 (MBY10-7A/pAM13-2), and sec12-4/vector (MBY10-7A/pYO326) were incubated at the indicated temperatures for 4 days. B, immunoblotting of sec12 ts mutant cells carrying plasmid-borne single-copy (CEN) or multicopy (2µ) sec12-4 with antibodies against Sec12p, Sar1p, Pgk1p, and CPY. For the case of Sec12p, the lysates were treated with endoglycosidase H to remove N-linked oligosaccharides. Cells of sec12-4 RST2 (MBY10-7A), sec12-4 rst2-1 (STR2), sec12-4/CEN sec12-4 (MBY10-7A/pAM13-2), and sec12-4/2µ sec12-4 (MBY10-7A/pAM13-3) were precultured at 23 °C (for sec12) or 30 °C (for sec12-4 rst2-1), cultured for 0 and 2 h at 37 °C, and then harvested and analyzed by immunoblotting. p1 and m indicate the ER form and the mature form of CPY, respectively.

Cloning of the Gene That Complements the rst2 Mutation: HRR25-- For the cloning of the RST2 gene, STR2, the original cold-sensitive rst2-1 sec12 mutant strain, was transformed with a yeast genomic DNA library constructed on the multicopy plasmid YEp13 (10). DNA clones that rescued the cold-sensitive growth were selected. One clone named P2-3 showed good complementation and was analyzed further. The 6.7-kb insert of P2-3 contained two complete ORFs, HRR25 and TPK2/PKA3 (see Fig. 3A). To localize the complementation activity of rst2-1 in this insert, deletion analysis was performed. Various fragments from P2-3 were subcloned into a multicopy plasmid, pQR324, or a single-copy CEN plasmid, pRS314, and introduced into the rst2-1 sec12-4 mutant (STR2). Transformants were tested for growth at the restrictive temperature for rst2-1, 15 °C. As shown in Fig. 3A, DNA fragments always complemented the rst2 mutant when they contained HRR25. The presence or absence of TPK2 did not correlate with the complementation activity. The same results were obtained for both the multicopy and single-copy plasmids. Thus, it is the HRR25 gene that complemented rst2-1. STR2 cells show morphological abnormality as well (5). The cells do not separate very well after division and tend to aggregate either in liquid or on plate culture. The DNA fragment containing HRR25 not only resumed the growth defect of STR2 at 15 and 23 °C (Fig. 3B), it also remedied this aggregation phenotype (Fig. 3C).


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 3.   Cloning of RST2 and its identification as HRR25. A, subclones of the original clone, P2-3, were examined for complementation of the growth defect of rst2-1. The thick arrow indicates the coding region of HRR25 and its direction of transcription. The dashed regions are derived from the vector, YEp13. Bars below show subclones. Note that HRR25 is necessary and sufficient for the ability to complement rst2-1. Abbreviations of restriction enzymes are: N, NheI; S, SphI; Xh, XhoI; Nc, NcoI; P, PvuII; Hp, HpaI; H, HindIII; B, BstBI; RV, EcoRV. B and C, the cold-sensitive growth defect (B) and the aggregation phenotype of the rst2-1 cells (STR2) at 30 °C (C) were completely complemented by HRR25.

To confirm that HRR25 is the authentic RST2 gene, the fragment containing HRR25 with the LEU2 marker was integrated at the HRR25 locus in the sec12-4 mutant, MBY10-7C. The integrant was mated with STR2 which was transformed by pAM2-326, a URA3-marker multicopy plasmid containing HRR25 derived from pYO326. This plasmid complemented rst2-1 and dramatically improved the mating and sporulation efficiency of the mutant. The diploid cells were sporulated, and the progeny haploid cells were plated on MVD (complete supplement) containing 5-fluoroorotic acid (FOA) at 27 °C to remove pAM2-326. Among 160 spores analyzed, 67 spores showed Leu- Cs- phenotype, 90 spores were Leu+ Cs+, 1 was Leu+ Cs-, and 2 were Leu- Cs+. This result indicated that the LEU2 marker was tightly linked to the Cs+ phenotype, namely HRR25 was linked to the rst2-1 locus. Therefore, we concluded that RST2 is identical to HRR25. Finally, we renamed our mutant allele (rst2-1) of HRR25, hrr25-2.

hrr25-2 (rst2-1) Is a Mutant with a Reduced Kinase Activity-- HRR25 encodes a dual-specificity casein kinase I (CKI) (17). We isolated the mutant hrr25-2 gene by the allele recovery method and determined that it contained a mutation of the C527T replacement in the nucleotide sequence, which caused T176I mutation in the amino acid sequence (Fig. 4A). A comparison of the amino acid sequence of Hrr25p with other yeast CKIs is shown in Fig. 4B. The T176I mutation is in the region conserved in all members of the yeast CKI family. To examine whether hrr25-2 is a kinase-minus (low kinase activity) or constitutively active mutation, we carried out an in vitro kinase assay for the Hrr25 protein from the wild-type and mutant cells (Fig. 5). HA-tagged versions of the HRR25 and hrr25-2 genes were constructed for this purpose. 3HA-HRR25 complemented the mutant phenotypes of Delta hrr25 and hrr25-2 (data not shown). The 3HA-tagged Hrr25p was immunoprecipitated with the anti-HA antibody and subjected to the kinase assay. The result of SDS-PAGE and autoradiography is shown in Fig. 5B. By the incubation with [gamma -32P]ATP, the immunoprecipitated 3HA-Hrr25p phosphorylated Hrr25p itself and casein as a substrate, but not histone H1 or myelin basic protein (lanes 2 and 4-6). In clear contrast, virtually no phosphorylated bands were observed when 3HA-Hrr25-2p was immunoprecipitated (lane 3). The amounts of 3HA-Hrr25p and 3HA-Hrr25-2p in the immunoprecipitates were almost the same as examined by immunoblotting (Fig. 5A). Thus, we conclude that hrr25-2 is a mutation with a markedly reduced kinase activity.


View larger version (87K):
[in this window]
[in a new window]
 
Fig. 4.   The mutation point of hrr25-2. A, illustration of the HRR25 gene product (Hrr25p). T176I is the mutation point of hrr25-2 (= rst2-1). Note that Hrr25p contains a region rich in proline and glutamine residues at the C terminus (Pro/Gln-rich). B, comparison of amino acid sequences in the kinase homology region between Hrr25p and other yeast CKIs. Black boxes represent the residues identical among the four CKIs, and the asterisk indicates the hrr25-2 mutation.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 5.   In vitro kinase assay of the Hrr25 T176I and K38A mutant proteins. A, Delta hrr25 cells (AMY7-4B) expressing no-tagged HRR25, 3HA-tagged HRR25, 3HA-tagged hrr25-2 (T176I), and 3HA-tagged hrr25 K38A were lysed and subjected to immunoprecipitation with the anti-HA monoclonal antibody (12CA5). The immunoprecipitates were examined for the amount of HA-tagged Hrr25 protein by immunoblotting with the anti-HA monoclonal antibody (16B12). B, a kinase assay was performed in the presence of [gamma -32P]ATP, and the phosphorylated products were analyzed by SDS-PAGE and autoradiography. As substrates, casein (lanes 1, 3, 4, and 7), histone H1 (lane 5), and myelin basic protein (lane 6) were added to the assay solution. The mobilities of molecular weight markers are shown on the left.

Furthermore, we constructed another mutant version of 3HA-tagged HRR25 (3HA-hrr25 K38A) by site-directed mutagenesis, which was also expected to be kinase-minus, and to act dominantly on the wild-type protein when overproduced. In the immunoprecipitation kinase assay (Fig. 5, lane 7), in fact, we could not detect any kinase activity of 3HA-Hrr25p K38A. As shown in Fig. 6A, the overproduction of Hrr25p K38A slightly suppressed the growth defect of sec12-4 at 35 °C. On the other hand, it inhibited the growth of sec23-1 and sar1-2 at 30 and 33 °C, respectively, and that of the wild-type slightly at 35 °C.


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 6.   Overexpression of the dominantly acting kinase-minus mutant of Hrr25p (3HA-Hrr25p K38A) in the sec12-4 mutant and Delta hrr25 sec12-4 double mutant cells. A, multicopy (2µ), GAL1-promoter-driven HA-tagged hrr25 K38A (K38A), or vector alone (vector) was expressed in sec12-4 (MBY10-7A), sec23-1 (MBY8-20C), sar1-2 (TOY224), and wild-type (ANY21) cells. Overnight liquid cultures of these transformants were diluted from 1 × 107 to 1 × 103 cells/ml by 10-fold serial dilution (A, left to right), and 5 µl each of diluted samples were spotted on MCGS plates. The cells were cultured for 8 days at the indicated temperatures. B, the Delta hrr25 sec12-4 mutant cells harboring HRR25 (pAM2-326: URA3-marked multicopy plasmid) were transformed with multicopy, own-promoter-driven hrr25-2 (T176I), HA-tagged HRR25 (HRR25), hrr25 K38A (K38A), or vector alone. The transformants were cultured for 6 days at 26 °C on MCD plates (complete supplements) containing 5-fluoroorotic acid to remove pAM2-326, and then restreaked on MCD (minus tryptophan) plates and cultured for 14 days at 26 and 35 °C.

Reduction of the Kinase Activity but Not Complete Loss of Hrr25p Is Important for the sec12-4 Suppression-- A HRR25 disruption was generated by inserting the 1.8-kb BamHI fragment of HIS3 from pJJ215 into the AflII-NdeI sites of HRR25. This disrupted gene was introduced on an integration vector into the wild-type diploid, YPH501. The resulting heterozygous diploid was sporulated and subjected to tetrad dissection. Fast and slow growing spores segregated 2:2. All the slow growth spores showed His+ phenotype. The correct integration at the HRR25 locus was confirmed by Southern blotting (data not shown). This indicates that these slow growing spores were the Delta hrr25 mutant. This observation is consistent with the results of Hoekstra et al. (17), i.e. HRR25 is not essential but very important for cell viability. Delta hrr25 showed extremely slow growth at low (15 °C) and high (37 °C) temperatures.

If the suppression of sec12-4 by hrr25-2 was due to the reduction of the Hrr25p kinase activity, the disruption of HRR25 would also suppress the sec12-4 growth defect. To test this, the Delta hrr25 mutant cells harboring pAM2-326 (2µ HRR25 URA3) were mated with the sec12-4 mutant (MBY10-7C). This diploid was sporulated, and tetrads were dissected to obtain segregants of the genotype, Delta hrr25 sec12-4. The spores showed a 2:2 segregation pattern regarding the sec12-4 phenotype as marked by growth Ts- on MCD (-Ura) plates. If these spores were cultured on FOA-containing plates at 15 °C, they also showed a 2:2 segregation pattern, because Delta hrr25 cells were extremely slow in growth at low temperature (15 °C). We selected segregants that are Ts- on MCD (-Ura) and Cs- on FOA plates, which have the genotype of Delta hrr25 sec12-4. The segregants were grown on FOA plates at 27 °C to lose the HRR25 plasmid and examined for growth at high temperatures. As shown in Table I, they were all unable to grow on YPD plates at either 35 or 37 °C. This result indicates that Delta hrr25 cannot suppress the sec12 mutation and suggests that hrr25-2 is not a null mutation in terms of the sec12 suppression. We also constructed double mutants of hrr25-2 with sec13-1, sec23-1, and ret1-1, but no clear suppression was observed.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Analysis of segregants from Delta hrr25 × sec12-4

To further analyze the relationship between the kinase activity and the sec12 suppression, the two mutant alleles of HRR25, hrr25 K38A and hrr25 T176I, were expressed in the Delta hrr25 sec12-4 double mutant cells. As shown in Fig. 6B, Delta hrr25 sec12-4 hardly grew at 35 °C. The mutant cells expressing HRR25 did not grow at 35 °C, either, due to the sec12-4 mutation. However, the expression of hrr25 K38A or hrr25 T176I suppressed the growth defect at 35 °C at least to some extent.

    DISCUSSION

In this paper, we have shown evidence for the first time that Hrr25p, a yeast CKI, is involved in vesicle budding from the endoplasmic reticulum.

Family of Yeast CKI-- CKI is an expanding family of kinases, which have been proposed to play a variety of roles in many cellular processes. Among five defined isoforms of mammalian CKI (18-20), for example, the alpha  isoform has been implicated in the regulation of secretion (21).

The yeast S. cerevisiae possesses four genes that encode CKI: YCK1, YCK2, YCK3, and HRR25. The redundant YCK1 and YCK2 genes are required for cell viability (22) and morphogenesis (23). Recently, several reports have suggested that YCK1, YCK2, and YCK3 are involved in vesicular transport through the studies of their genetic interactions. For example, suppressor mutations of the yck1Delta yck2-2 mutant (yckts) define four subunits of a novel clathrin AP-like complex, AP-3 (24). The yckts mutant shows a strong synthetic growth defect with chc1-ts (24), and exhibits ts phosphorylation, ubiquitination, and endocytosis of the alpha -factor receptor (25). YCK1, YCK2, and YCK3 suppress the defect of the deletion of GCS1, a yeast ARF GTPase-activating protein gene (26, 27) , in cell proliferation from the stationary phase (28). HRR25 forms an essential gene pair with YCK3 but cannot suppress the Delta gcs1 mutant. These relationships are illustrated in Fig. 7. In contrast to such implications of YCK1, YCK2, and YCK3 in vesicular traffic, HRR25 was originally proposed to carry out other important function(s). The HRR25 gene was identified by a mutation that conferred sensitivity to the expression of HO. HO is a gene coding for a 65-kDa endonuclease, which performs site-specific cleavage of double-stranded DNA, and is essential for the initiation of mating-type interconversion. Using a yeast strain harboring a galactose-inducible HO gene, Hoekstra et al. (17) isolated mutants that were unable to grow on galactose-containing medium. One of the mutants, hrr25-1, showed sensitivity to continuous expression of the HO double-strand endonuclease, to methylmethanesulfonate, and to x-ray irradiation. The hrr25-1 mutant cells not only had a defect in DNA double-strand break repair, but also showed poor sporulation, very slow growth, and cell cycle delay in G2 (17).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 7.   Genetic interactions between yeast CKIs and components involved in vesicular transport. See "Discussion" for details. AP-3, adaptor protein complex 3; GCS1, a gene encoding GTPase-activating protein of ARF; CHC1, the gene encoding clathrin heavy chain.

Yck1p, Yck2p, and Yck3p have a motif of prenylation (GCC) in their C termini, and in fact Yck2p is tightly associated with the plasma membrane (29). Hrr25p does not have the prenylation motif, but was also found exclusively in membrane fractions in differential centrifugation analysis; HA-tagged Hrr25p cofractionated with plasma membrane and nuclei (29). DeMaggio et al. (30) predicted that Hrr25p is a multipotential protein kinase, generating phosphothreonine and phosphoserine. They detected Hrr25p-dependent phosphorylation of nonspecific proteins found in the Hrr25p immunoprecipitates by autoradiography. Hrr25p was also able to phosphorylate tyrosine residues when the protein was expressed in Escherichia coli (31). Ho et al. (13) reported that Swi6p was phosphorylated by Hrr25p in their in vitro kinase assay. Swi6p interacts with Swi4p to form the SBF (SCB (Swi4/Swi6 cell cycle box)-binding factor) complex, which acts as a transcription factor for some G1 cyclin genes, HO, and genes involved in transcriptional response to DNA damage.

HRR25 in Vesicular Transport-- We have shown in the present study that rst2-1, an extragenic suppressor of sec12-4, is a new mutant allele of HRR25 (hrr25-2). The hrr25-2 mutation not only suppresses the ts growth of sec12-4, but in fact resumes the secretion defect of sec12-4. The hrr25-2 mutant cells grow slowly; their doubling time is approximately 4-5 times longer than that of the wild-type. However, the resumed kinetics of CPY transport is as fast as in the wild-type. Thus, besides the functions in DNA damage repair and cell cycle control, Hrr25p must play some role in the secretory transport pathway.

hrr25-2 harbors a mutation that causes the amino acid replacement T176I. This residue is conserved among the four yeast CKIs and the mutant Hrr25 T176I protein with an HA tag showed little kinase activity. We constructed another mutant allele of HRR25 that causes the K38A replacement. This residue is also conserved in the kinase domain, and the mutant protein was shown to have lost the kinase activity. The overexpression of Hrr25p K38A also suppressed the ts growth of sec12-4, although weakly. These results suggest that it is the decrease of the kinase activity that is important for Hrr25p to suppress sec12-4. However, the deletion of HRR25, which is not a lethal event, did not suppress sec12-4.

Two reasons can be considered to explain the difference between the loss-of-function-type missense mutations (T176I and K38A) and the null mutation. The hrr25 deletion is not lethal, but the disruptant cells are quite sick. They grow very poorly at 30 °C and are almost inviable at high and low temperatures. Perhaps the null mutant cells have so many problems to sustain growth, and even though the loss of activity had a remedial effect on sec12-4, other lesions may have concealed such suppression. The alternative, more intriguing possibility is that the presence of the mutant protein is required for the suppression. The observation that the overproduction of Hrr25p T176I or K38A allowed the growth of the Delta hrr25 sec12-4 double mutant up to 35 °C supports this possibility.

Although the interaction between the active kinase and substrates may be transient, a kinase-inactive mutant may form a stable protein-protein complex. In mitogen-activated protein kinase pathways, some substrates have been identified by two-hybrid screening with such a kinase-minus mutant as a bait (32-34). It is possible that Hrr25p T176I or K38A binds to its substrate(s) very tightly and, by doing so, releases the budding block of sec12-4. There are some differences between Hrr25p T176I and K38A. For example, the overexpression of Hrr25p K38A suppresses Delta hrr25 sec12-4 better than that of Hrr25p T176I, even though K38A appears to be more severely impaired in the kinase activity. This could be explained by the positions of mutations; K38A is in the ATP-binding site and T176I is in a putative substrate recognition site.

Target of Hrr25p in Vesicular Traffic-- Sec12p is not phosphorylated under a normal condition of vegetative growth as far as we examined by in vivo labeling experiments,2 and is thus unlikely to be a substrate of Hrr25p. This led us to postulate that the target of the Hrr25p in vesicular transport is a negative regulator of the Sec12p function. It could be directly regulating the function of Sec12p or might transduce a signal to control vesicle budding reactions. Then, what is this putative regulator? Sec31p, one of the COPII components, was a good candidate because it had been shown to be a phosphoprotein and the phosphatase treatment of Sec13p/Sec31p complex inhibited vesicle budding (35). However, Sec31p was still phosphorylated in the hrr25-2 mutant cells, and the purified Sec13p/Sec31p complex was not subject to phosphorylation by 3HA-Hrr25p in our in vitro kinase assay.2 At the moment, we have not yet been able to identify in vivo or in vitro substrates of Hrr25p as candidates of the regulator of the Sec12p function. Considering the possibility that the titration of a regulator of Sec12p by the kinase-minus Hrr25p mutant (K38A or T176I) is the cause of the sec12 suppression, this regulator might not necessarily be a substrate of the Hrr25p kinase.

The mutations in HRR25 could also invoke vesicle budding from the ER in sec12-4 cells by bypassing the requirement of Sec12p or COPII components. However, hrr25-2 does not suppress the complete loss of Sec12p2 or the temperature sensitivity of COPII mutants, such as sec13-1 and sec23-1. Furthermore, although hrr25 K38A suppresses sec12-4, it rather aggravates the temperature sensitivity of some mutations in COPII, such as sar1-2 and sec23-1. Specific suppression of sec12-4 by hrr25-2 implies again the important role of Sec12p in the regulation of vesicle budding. Our further work on the target(s) of Hrr25p will help unveil the mechanisms of how the earliest event of vesicle budding is controlled in living cells.

    ACKNOWLEDGEMENTS

We are grateful to Howard Riezman (University of Basel, Basel, Switzerland) for the anti-Gas1p antibody, Randy Schekman (University of California, Berkeley, CA) for the Sec13p/Sec31p complex and the anti-Sec31p antibody, Hiroshi Qadota (Nara Institute of Science and Technology, Nara, Japan) for a plasmid, and the members of the Nakano laboratory for helpful discussions.

    FOOTNOTES

* This work was supported in part by grants-in-aid from the Ministry of Education, Science and Culture of Japan and by a fund from the Biodesign Project of RIKEN.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Supported by a postdoctoral fellowship from RIKEN and by a research grant from the Human Frontier Science Program Organization.

parallel To whom correspondence should be addressed. Fax: 81-48-462-4679; E-mail: nakano{at}postman.riken.go.jp.

The abbreviations used are: ER, endoplasmic reticulum; CKI, casein kinase I; CPY, carboxypeptidase Y; GEF, guanine nucleotide exchange factor; HA, hemagglutinin; ts, temperature-sensitive; DTT, dithiothreitol; ORF, open reading frame; PCR, polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis; FOA, 5-fluoroorotic acid; kb, kilobase pair(s) .

2 A. Murakami, unpublished data.

    REFERENCES
Top
Abstract
Introduction
References

  1. Nakano, A., and Muramatsu, M. (1989) J. Cell Biol. 109, 2677-2691[Abstract]
  2. Barlowe, C., Orci, L., Yeung, T., Hosobuchi, M., Hamamoto, S., Salama, N., Rexach, M. F., Ravazzola, M., Amherdt, M., and Schekman, R. (1994) Cell 77, 895-907[Medline] [Order article via Infotrieve]
  3. Barlowe, C., and Schekman, R. (1993) Nature 365, 347-349[CrossRef][Medline] [Order article via Infotrieve]
  4. Oka, T., and Nakano, A. (1994) J. Cell Biol. 124, 425-434[Abstract]
  5. Nakano, A. (1996) J. Biochem. (Tokyo) 120, 642-646[Abstract]
  6. Nakano, A., Brada, D., and Schekman, R. (1988) J. Cell Biol. 107, 851-863[Abstract]
  7. Sikorski, R. S., and Hieter, P. (1989) Genetics 122, 19-27[Abstract/Free Full Text]
  8. Jones, J. S., and Prakash, L. (1990) Yeast 6, 363-366[Medline] [Order article via Infotrieve]
  9. Ohya, Y., Goebl, M., Goodman, L. E., Petersen-Bjørn, S., Friesen, J. D., Tamanoi, F., and Anraku, Y. (1991) J. Biol. Chem. 266, 12356-12360[Abstract/Free Full Text]
  10. Yoshihisa, T., and Anraku, Y. (1989) Biochem. Biophys. Res. Commun. 163, 908-915[Medline] [Order article via Infotrieve]
  11. Takita, Y., Ohya, Y., and Anraku, Y. (1995) Mol. Gen. Genet. 246, 269-281[Medline] [Order article via Infotrieve]
  12. Tyers, M., Tokiwa, G., Nash, R., and Futcher, B. (1992) EMBO J. 115, 1773-1784
  13. Ho, Y., Mason, S., Kobayashi, R., Hoekstra, M. F., and Andrews, B. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 581-586[Abstract/Free Full Text]
  14. Schimmöller, F., Singer-Krüger, B., Schröder, S., Krüger, U., Barlowe, C., and Riezman, H. (1995) EMBO J. 14, 1329-1339[Abstract]
  15. Doering, T. L., and Schekman, R. (1996) EMBO J. 15, 182-191[Abstract]
  16. d'Enfert, C., Barlowe, C., Nishikawa, S., Nakano, A., and Schekman, R. (1991) Mol. Cell. Biol. 11, 5727-5734[Medline] [Order article via Infotrieve]
  17. Hoekstra, M. F., Liskay, R. M., Ou, A. C., DeMaggio, A. J., Burbee, D. G., and Heffron, F. (1991) Science 253, 1031-1034[Medline] [Order article via Infotrieve]
  18. Rowels, J., Slaughter, C., Moomaw, C., Hsu, J., and Cobb, M. H. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 9548-9552[Abstract]
  19. Graves, P. R., and Roach, P. J. (1995) J. Bilo. Chem. 270, 21689-21694[Abstract/Free Full Text]
  20. Fish, K. J., Cegielska, A., Getman, M. E., Landes, G. M., and Virshup, D. M. (1995) J. Biol. Chem. 270, 14875-14883[Abstract/Free Full Text]
  21. Gross, S. D., Hoffman, D. P., Fisette, P. L., Baas, P., and Anderson, R. A. (1995) J. Cell Biol. 130, 711-724[Abstract]
  22. Robinson, L. C., Hubbard, E. J. A., Graves, P. R., DePaoli-Roach, A. A., Roach, P. J., Kung, C., Haas, D. W., Hagedorn, C. H., Goebl, M., Culbertson, M. R., and Carlson, M. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 28-32[Abstract]
  23. Robinson, L. C., Menold, M. M., Garrett, S., and Culbertson, M. R. (1993) Mol. Cell. Biol. 13, 2870-2881[Abstract]
  24. Panek, H. R., Stepp, J. D., Engle, H. M., Marks, K. M., Tan, P. K., Lemmon, S. K., and Robinson, L. C. (1997) EMBO J. 16, 4194-4204[Abstract/Free Full Text]
  25. Hicke, L., Zanolari, B., and Riezman, H. (1998) J. Cell Biol. 141, 349-358[Abstract/Free Full Text]
  26. Ireland, L. S., Johnston, G. C., Drebot, M. A., Dhillon, N., DeMaggio, A. J., Hoekstra, M. F., and Singer, R. A. (1994) EMBO J. 13, 3812-3821[Abstract]
  27. Poon, P. P., Wang, X., Rotman, M., Huber, I., Cukierman, E., Cassel, D., Singer, R. A., and Johnston, G. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10074-10077[Abstract/Free Full Text]
  28. Wang, X., Hoekstra, M. F., DeMaggio, A. J., Dhillon, N., Vancura, A., Kuret, J., Johnston, G. C., and Singer, R. A. (1996) Mol. Cell. Biol. 16, 5375-5385[Abstract]
  29. Vancura, A., Sessler, A., Leichus, B., and Kuret, J. (1994) J. Biol. Chem. 269, 19271-19278[Abstract/Free Full Text]
  30. DeMaggio, A. J., Lindberg, R. A., Hunter, T., and Hoekstra, M. F. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 7008-7012[Abstract]
  31. Hoekstra, M. F., Dhillon, N., Carmel, G., DeMaggio, A. J., Lindberg, R. A., Hunter, T., and Kuret, J. (1994) Mol. Biol. Cell 5, 877-886[Abstract]
  32. Han, J., Jiang, Y., Li, Z., Kravchenko, V. V., and Ulevitch, R. J. (1997) Nature 386, 296-299[CrossRef][Medline] [Order article via Infotrieve]
  33. McLaughlin, M. M., Kumar, S., McDonnell, P. C., Horn, S. V., Lee, J. C., Livi, G. P., and Young, P. R. (1996) J. Biol. Chem. 271, 8488-8492[Abstract/Free Full Text]
  34. Zhou, G., Bao, Z. Q., and Dixon, J. E. (1995) J. Biol. Chem. 270, 12665-12669[Abstract/Free Full Text]
  35. Salama, N. R., Chuang, J. S., and Schekman, R. W. (1997) Mol. Biol. Cell 8, 205-217[Abstract]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.